01177 SINO BIOPHARM
- 2.450
- -0.010-0.41%
SINO BIOPHARM News
China Galaxy Securities: Innovation and transformation are accelerating into the performance harvest period, and China Biopharmaceutical (01177.HK) was first awarded a “recommended” rating
China Biopharmaceutical (1177.HK): Leading pharmaceutical companies accelerate transformation and innovative businesses into a harvest period
BOC International: Maintaining China Biopharmaceutical's (01177.HK) “Buy” Rating Target Price of HK$4.8
China Biopharmaceutical (1177.HK): Major BD hits the tumor pipeline and continues to improve the layout of differentiated targets/indications for solid tumors
China Biopharmaceutical (1177.HK): BI strategic cooperation opens domestic oncology pipeline to the next level
Big Bank Rating | Dahua Jixian: Raising the target price of Zhongsheng Pharmaceuticals to HK$3.8 and upgrading the rating to “buy”
Research Nuggets | CICC: Lowering the target price of Zhongsheng Pharmaceuticals to HK$4.2 to maintain “outperforming the industry” rating
China Biopharmaceutical (1177.HK): Remarkable results in cost reduction and efficiency, innovation and transformation welcome the harvest period
China Biopharmaceutical (1177.HK) Company Research: Remarkable Results in Cost Reduction and Efficiency, Innovation and Transformation Reach the Harvest Period
SINO BIOPHARM(1177.HK):2023 RESULTS MISSED;FOCUS ON FOUR CORE THERAPEUTIC FIELDS
Bank Rating | Bank of America: Lowering the target price of Zhongsheng Pharmaceuticals to HK$3.6 to maintain a “buy” rating
China Biopharmaceutical (1177.HK): Innovation enters the harvest period and continues to advance in four major fields
China Biopharmaceutical (1177.HK): Strong performance in 2023, resilient R&D results, accelerated delivery, expected growth recovery, and raised target prices
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.16 From HK$6.63, Keeps at Buy
Nomura: Reiterates China Biopharmaceutical's (01177) “Buy” Rating Target Price Reduction to HK$6.16
Bank Rating | Citibank: Lowering the target price of Zhongsheng Pharmaceuticals to HK$7.4 to maintain a “buy” rating
Nomura: Target price of HK$6.63 for a “buy” rating for China Biopharmaceuticals (01177)
Research and Development | Haitong Securities: Maintaining China Biopharmaceuticals' “Better Than Market” Rating Target Price of HK$5.98
Haitong Securities: Maintaining China Biopharmaceutical's (01177) “Better Than Market” Rating Target Price of HK$5.98
China Biopharmaceutical (01177.HK) follow-up review: reversing endogenous business difficulties, BD accelerates continuous improvement of the governance structure
Analysis
Price Target
No Data
